-+ 0.00%
-+ 0.00%
-+ 0.00%

SATELLOS CHANGES PRIMARY EFFICACY ENDPOINT IN BASECAMP PHASE 2 PEDIATRIC TRIAL TO MRI-MEASURED FAT FRACTION FOLLOWING FDA FEEDBACK

Reuters·11/06/2026 12:00:00

Please log in to view news